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Preeclampsia and stroke are signiﬁcantlyrelated, both pathologically and temporally (across the life span) in women. Cerebrovas-
cularevents cancomplicatepreeclampsia,andcanalsomanifestlater inlife.Ahistory ofpreeclampsia is associatedwithlong-term
risk for hypertension, stroke, and heart disease. Cerebrovascular complications occur in only a small proportion of women with
severe preeclampsia, but with high morbidity and mortality. Endothelial dysfunction and impaired cerebral autoregulation, and
severe hypertension in the setting of preeclampsia are likelythe cause ofmany strokes during pregnancy. The relationshipbetween
preeclampsia and stroke involves shared risk factors for both disorders, including chronic endothelial dysfunction and increased
risk for long-term hypertension following preeclampsia (one of the major risk factors for stroke). This overlap provides insights
into underlying pathophysiology and potential preventive strategies for both preeclampsia and stroke. For example, aspirin may
prevent both disorders. The current review will describe the current data regarding these relationships and suggest future research
to investigate remaining knowledge gaps. These are important topics for neurologists, who are likely to be involved with the care
of severely ill preeclamptic patients with neurologic complications,as well as women at increased risk of stroke due to a history of
preeclampsia.
1.Introduction
While stroke is a leading cause of death in postmenopausal
women, it is a relatively uncommon occurrence during preg-
nancy. However, its morbidity and mortality are dispropor-
tionately high, especially in young women and newborn or
unborn children. The incidence of stroke during pregnancy
including cerebral venous thrombosis ranges from 10 to
34/100,000 deliveries [1–3]. One of the most common risk
factors for stroke in pregnancy, particularly postpartum, is
preeclampsia/eclampsia [2, 3]. In the most recent Nation-
wide Inpatient Sample epidemiological study of stroke in
pregnancy, preeclampsia/eclampsia was associated with a 4-
fold increased risk of stroke [2]. Preeclampsia is potentially
of interest to neurologists because it shares common patho-
physiologyandrisk factorswith stroke,includingendothelial
dysfunction, dyslipidemia, hypertension, hypercoagulability,
and abnormal cerebralvasomotorreactivity. Itisnot surpris-
ing then, that a history of preeclampsia during pregnancy
would lead to an increased risk of stroke later in life, as well
[4].Thepurposeofthisreviewistodescribewhatiscurrently
known about the epidemiology of preeclampsia as it related
to risk factors for stroke during pregnancy and in later life.
We will also identify areas where further research is needed.
2.The SpectrumofPreeclampsia/Eclampsia
Preeclampsia is classiﬁed as one ofthe hypertensive disorders
of pregnancy. It is generally deﬁned as new onset hyper-
tension with proteinuria during pregnancy, although the
term is also used to describe worsening blood pressure and
proteinuriainwomenwithahistoryofchronicprepregnancy2 Stroke Research and Treatment
hypertension [5] .T h em a t e r n a ls y n d r o m ec o n s i s t so fh y p e r -
tensionand proteinuria, which may alsoincludemultisystem
abnormalities such as hemolysis, elevated liver enzymes, or
low platelets (HELLP) syndrome; disseminated intravascular
coagulation (DIC); acute renal failure; seizures; pulmonary
edema [6]. The fetal syndrome includes fetal growth restric-
tion, small-size-for-gestational-age (SGA), reduced amniotic
ﬂuid, and placental insuﬃciency leading to fetal hypoxia and
hypoperfusion. Preeclampsia can occur near or before term,
with or without fetal complications [6].
Preeclampsia is categorized as mild or severe. Mild pree-
clampsia is deﬁned as blood pressure of at least 140mmHg
systolic or at least 90mmHg diastolic on at least two
occasions and at least 4 to 6 hours apart after the 20th week
of gestation in women without prepregnancy hypertension,
with proteinuria (deﬁned as ≥300mg protein in a 24 hour
urine specimen) [6]. Severe preeclampsia is deﬁned as blood
pressure atleast160or170mmHgsystolic, 110mmHgdias-
tolic, or both, accompanied by ≥5g of proteinuria per day.
Whensymptoms suchassevereheadache,visualdisturbance,
epigastric pain, vomiting, multiorgan system involvement,
fetal morbidity or mortality, onset before 34 or 35 weeks
or eclampsia (seizures) are present, preeclampsia is also
classiﬁed as severe (see Table 1). Eclampsia, deﬁned as tonic-
clonicseizuresin apregnantorrecentlydeliveredwoman not
attributable to other causes than preeclampsia or gestational
hypertension, complicatesabout1to 2%ofall casesofsevere
preeclampsia [7]. It is important to note that published
guidelines for preeclampsia diagnostic criteria vary among
diﬀerent professional societies [7].
3.EpidemiologyofPreeclampsia
Preeclampsia is part of the spectrum of hypertensive dis-
orders in pregnancy, which also includes gestational hyper-
tension (GH). GH is deﬁned as elevated blood pressure of
at least 140mmHg systolic or at least 90mmHg diastolic
without proteinuria in a woman after 20 weeks’ gestation,
which resolves postpartum [10]. Hypertensive disorders in
pregnancy aﬀect 8%–12% of all pregnancies, and this rate is
even higher in developing countries. About three quarters of
cases of preeclampsia in women are classiﬁed as mild, with
onset at or near-term [6]. Adverse outcomes are generally
rare in mild preeclampsia. However, it is important to
note that mild preeclampsia is a retrospective diagnosis.
Mild hypertension in pregnancy can evolve quickly and
unpredictably to fulminant severe preeclampsia. African
American women appear to be at higher risk for the devel-
opment of preeclampsia, although it is not clear whether this
relationship is due to a higher prevalence of hypertension
in African American women or other risk factors. Women
living at high altitude are also known to be at higher risk for
preeclampsia.
4.RiskFactorsforPreeclampsia
Multiple risk factors for preeclampsia have been identiﬁed
through clinical and large cohort studies. Many of these
risk factors overlap with those for stroke and cardiovas-
cular disease (CVD), such as family history, prepregnancy
hypertension, diabetes, obesity and insulin resistance, pre-
existing thrombophilia, renal disease, and collagen-vascular
disease [11]. Some pregnancy-speciﬁc and maternal risk
factors include maternal infections, extremes of maternal
age, multiple gestation, maternal low birthweight, hydrops
fetalis, and preeclampsia in a prior pregnancy [7, 12]
(see Duckitt et al. for comprehensive review). An unusual
protective factor against preeclampsia is maternal smoking,
for unclear reasons.
Immune and paternal factors may also aﬀect women’s
risk for preeclampsia. In a large birth cohort in Norway,
the rate of preeclampsia was 3.4% in women with their
ﬁrst pregnancy, whereas the rate of preeclampsia in the
second pregnancy with the same father was 1.7%; other
studies have noted an increase in the risk for preeclampsia
with a change in paternity, limited sperm exposure with
the same partner, or increased duration of time between
pregnancies [13]. These ﬁndings suggested that an immune
tolerance mechanism contributes to the pathogenesis of
preeclampsia [14]. This theory has recently been challenged
by ﬁndings that preterm preeclampsia is more likely to
recur than term preeclampsia, which is not consistent with
an immune-mediated mechanism. Preterm preeclampsia is
also more likely to be associated with long-term CVD,
which implicates maternal factors as being important in its
pathogenesis [15]. Other paternal factors have been shown
to contribute to the risk for preeclampsia. In the Norwegian
study cited above, men who fathered one preeclamptic
pregnancy were 1.8-fold as likely to father a preeclamptic
pregnancy in a diﬀerent woman (OR 1.8; 95% CI 1.2–
2.6) [14]. Preeclampsia has a clear genetic component.
In an intergenerational study of paternal and maternal
contributionsto the risk ofdevelopingpreeclampsia, women
whose mothers had preeclampsia were more likely to have
the condition in their own pregnancies. Men born after a
pregnancy complicated by preeclampsia were more likely to
father a pregnancy complicated by preeclampsia, and for
both women and men, familial preeclampsia was associated
with more severe preeclampsia in the index pregnancy [16].
A novel risk factor for preeclampsia may be migraine.
Thereisagrowingbodyofliteraturetosuggestanassociation
between migraine and preeclampsia, although no cause
and eﬀect has been established. The symptomatology of
both conditions may overlap, since severe preeclampsia
may involve headache with visual scotoma [7], similar to
migraine with aura. A review of all cross-sectional, case-
control, and cohort studies published prior to 2006 revealed
10 studies that examined the association between migraine
and preeclampsia, 8 of which showed a positive and sig-
niﬁcant relationship [17]. Since then, at least 2 additional
studies have been published. In a large study of delivery hos-
pitalization discharges in the Nationwide Inpatient Sample,
over 34,000 women had a primary or secondary discharge
diagnosis of peripartum migraine [18]. The association
between preeclampsia and migraine (OR 2.29, 95% CI
2.13–2.46) was so robust that preeclampsia diagnosis codes
had to be excluded in order to analyze the associationStroke Research and Treatment 3
Table 1: Criteria for classiﬁcationof severe preeclampsia [8, 9].
Severity Criteria Recommendations from SOGC and ASH
Gestational age at onset Less than 34 to 35 weeks’ gestation
Maternal symptoms Persistent or new/unusual headache; visual disturbances; persistent abdominal or right upper quadrant
pain; severe nausea or vomiting; chest pain or dyspnea
Maternal signs of end-organ
dysfunction
Eclampsia;severe hypertension (>160/110mmHg); pulmonary edema; suspected placental abruption;
severe diastolic hypertension (>110mmHg); heavy proteinuria (3g/day) or oliguria
Abnormal maternal laboratory
testing
Raised serum creatinine; increased AST, ALT, or LDH with symptoms; platelet count <100 × 109/L; or
serum albumin <20g/L; decreased glomerular ﬁltration rate
Fetal morbidity or mortality Oligohydramnios;intrauterine growth restriction; absent or reversed end-diastolic ﬂow in umbilical
artery by Doppler velocimetry; intrauterine fetal death; any fetal morbidity (non-reassuring fetal testing)
SOGC: Society of Obstetricians and Gynaecologists of Canada; ASH: American Society of Hypertension; AST: aspartate transaminase; ALT: alanine transam-
inase; LDH: lactate dehydrogenase.
between migraine and stroke [18]. A case control study
from Peru showed an incrementally stronger relationship
between preeclampsia and any headache before or during
pregnancy (OR 2.4, 95% CI 1.7–3.3), migraine prior to
pregnancy (OR 3.5, 95% CI 1.9–6.4), and migraine during
pregnancy (OR 4.0, 95% CI 1.9–9.2) [19]. The mechanism
f o rt h i sa s s o c i a t i o ni sc u r r e n t l yu n k n o w n ,b u tm a yr e l a t et o
endothelial dysfunction, widely recognized as important in
the pathophysiology of both conditions [17–20].
5.Risksof CerebrovascularDisease in
WomenwithPreeclampsia
Fewer than 1% of women with preeclampsia suﬀer from
stroke during the puerperium (the ﬁrst six weeks postpar-
tum). However, among women with stroke during preg-
nancy, preeclampsia/eclampsia is an important risk factor
for both ischemic and hemorrhagic strokes. For example, in
a French case series of 31 women with stroke during preg-
nancy, about half (n = 15) were ischemic, with preeclamp-
sia/eclampsia accounting for 6 cases or 47%. Of those with
hemorrhagic strokes, 7 (44%) had eclampsia, in addition to
HELLP syndrome or disseminated intravascular coagulation
[21]. A Canadian case series reported that 7 of 34 or 21%
of women with peripartum stroke had preeclampsia [1]. In
Taiwan, 7 of 19 or 37% of women with peripartum stroke
had preeclampsia/eclampsia or hypertensive intracerebral
hemorrhage [22]. These single-center case series are limited
due to the small sample sizes, but larger cohort studies
have conﬁrmed this association. The Nationwide Inpatient
Sample analysis from 2000 to 2001 reported that preeclamp-
sia was associated with a 4-fold increase in stroke during
pregnancy (OR 4.4; 95% CI 3.6–5.4) [2]. A limitation of this
study, as with most administrative databases, was the need to
rely on correct assignment of ICD-9 codes and the inability
to review medical records to collect individual level patient
details.
Hemorrhagic stroke is the most common stroke type
associated with pregnant or postpartum women with
preeclampsia/eclampsia.DatafromtheNationwideInpatient
Sample examining women aged 15 to 44 showed that most
cases of pregnancy-associated hemorrhagic strokes occurred
postpartum [23]. The risk factors independently associated
with hemorrhagic stroke included preexisting hypertension
(OR 2.6; 95% CI 1.34–5.07), gestational hypertension (OR
2.41; 95% CI 1.62–3.59), and preeclampsia/eclampsia (OR
10.4; 95% CI 8.3–13.0) [23]. The in-hospital mortality was
20%[23].Inadetailedseriesof27womenwithpreeclampsia
and subsequent stroke, 25 (89%) had hemorrhagic and
2 (7%) had ischemic stroke; 96% of these women had
headache, 63% with nausea and vomiting, 71% had symp-
toms attributable to the central nervous system (e.g., focal
weakness, seizure, syncope, decreased level of alertness), and
37.5% had visual problems [24]. Similar to the Nationwide
Inpatient Sample analysis, the majority (57%) of strokes
occurred postpartum. Another striking feature in this series
was that 96% of these women had prestroke systolic blood
pressures ≥160mmHg, whereas only 21% of women had
diastolic blood pressures >105mmHg. Not surprisingly,
given the high rate of hemorrhagic strokes, the mortality
was 54% [24]. The important message from this case series
was that, in contrast to current management protocols
which base treatment decisions on elevated diastolic blood
pressures, women with severepreeclampsia and highisolated
systolic blood pressures should be considered at high risk for
hemorrhagicstrokeandthatantihypertensivetherapyshould
be considered in these patients [24].
Besides ischemic and hemorrhagic stroke, preeclampsia
is often associated with the syndrome of reversible posterior
leukoencephalopathy syndrome (RPLS; also known as pos-
terior reversible encephalopathy syndrome or PRES) [25].
This disorder diﬀers pathophysiologically from ischemic or
hemorrhagic stroke because it is associated with reversible
vasogenic edema seen on CT or MRI, usually in the occipital
or parietal lobes [26, 27]. This disorder is thought to be
similartohypertensiveencephalopathyandisassociatedwith
seizures, headaches, encephalopathy, and reversible imaging
features. RPLS may occur in the setting of preeclampsia
due to impaired cerebral autoregulation from endothelial
damage. Large changes in blood pressure (rather than the
absolute blood pressure) can then result in an imbalance
of the capillary and cellular perfusion pressures, leading
to vasogenic edema [27, 28]. The treatment of this dis-
order includes blood pressure lowering and antiepileptics,
although most patients do not require treatment for seizures
beyond the acute syndrome.
Imaging in women with RPLS associated with the puer-
periumhas beendescribed asdiﬀuse ormultifocalsegmental4 Stroke Research and Treatment
vasoconstriction (or vasospasm) [28]. As this disorder is
increasingly recognized there are features that are considered
atypical compared with the original deﬁnition. For example,
in the largest case series of RPLS to date, over half of
the patients had signiﬁcant frontal involvement, in addition
to 5% that included hemorrhage and conﬂuent vasogenic
edema [26]. Also, about one quarter of these cases had
permanent injury, although the lesions were small on repeat
MRI. The imaging abnormalities resolved completely in
about two-thirds of cases in this series, which means that
thereare still a considerablenumber of patientswith residual
abnormalities [26].
A similar disorder that occurs in association with pree-
clampsia is reversible cerebral vasoconstriction syndromes
(RCVS). The classical presentation of RCVS, also known as
Call Fleming Syndrome, is a thunderclap headache, with or
withoutadditionalneurologicsigns[29].Diagnosticimaging
reveals multifocal segmental vasoconstriction of the cerebral
arteries, which usually resolves within days to weeks. Besides
occurring during the pregnancy or puerperium, this syn-
drome canoccur as an idiosyncratic response to medications
or illicit drugs, or without any identiﬁable cause. Although
the pathophysiologyofall ofthe vasoconstriction syndromes
is not fully understood, it involves a disturbance in the
controlofcerebralvasculartone.Inthe setting ofpreeclamp-
sia/eclampsia, the syndrome of RCVS usually occurs post-
partum (often labeled postpartum angiopathy) [29], and
in severe cases of eclampsia, superimposed cytotoxic edema
and chronic infarction may also occur [30]. Based on
imaging, this diagnosis may be diﬃcult to diﬀerentiate from
central nervous system vasculitis, thus analysis of spinal
ﬂuid may be helpful. Clinically, however, vasculitis usually
involves an insidious headache rather than the thunderclap
headache characteristic of RCV. The treatment of RCVS is
not standardized because it is not known whether the rapid
resolution of symptoms may be due to the natural history of
the syndrome or therapeutic strategies that are empirically
initiated. In conﬁrmed cases with imaging, calcium channel
blockers may be initiated, such as nimodipine or verapamil,
although caution should be employed to maintain cerebral
perfusion in watershed regions of a constricted artery [29].
Other medications have included high-dose glucocorticoids
[31] or magnesium sulfate [32].
The amount of overlap between RPLS and RCVS is
unclear because some of the larger case series of RPLS did
not include arterial imaging [26, 27]. We propose that there
is likely to be overlap in the pathophysiology and therefore
imaging characteristics of many of the cerebrovascular syn-
dromes associated with preeclampsia/eclampsia, as shown in
Figure 1.T h ep r i m a r yd i ﬀerence between RPLS and RCVS is
in the clinical symptoms. RCVS manifests in a thunderclap
headache, whereas RPLS is more likely to include seizures
and encephalopathy with nonthunderclap headache. As
noted above, because many women do not undergo brain
imaging, the true prevalence of cerebrovascular complica-
tions such as RPLS and RCVS is unknown. In addition,
guidelines recommend recognition and treatment of severe
preeclampsia, whether it includes severe hypertension or
the onset of severe headache or neurologic signs of any
RPLS
Preeclampsia,
severe
Ischemic
stroke
Reversible vasogenic
edema, subarachnoid
hemorrhage Intracerebral
hemorrhage
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kind [7]. Therapeutic maneuvers such as administration of
magnesium sulfate, glucocorticoids, antihypertensive ther-
apy, or delivery of the baby may also eﬀectively treat the
reversible syndrome and its clinical symptoms, resulting
in the inability to distinguish the two disorders. Because
of the urgency of delivering the infant and stabilizing the
mother, imaging may also not be performed commonly
unless clinically indicated. Therefore, it is possible that the
incidence of milder, subclinical forms of either RPLS or
RCVS on imaging is much higher than currently recognized.
Carefully designed pregnancy registries with detailed clinical
and neurological details may provide some insights into
the incidence of these disorder s .I na d d i t i o n ,n o n i n v a s i v e
monitoring with ultrasound, such as transcranial Doppler,
may also allow evaluation of the cerebral hemodynamics of
severe preeclampsia, although it is currently unclear which
parameters are most important to measure [33, 34].
6.ProposedPathophysiologyofPreeclampsia
The underlying cause of preeclampsia is still unknown,
but there are well-recognized combinations of placental,
immune, and vascular factors that lead to the condition. The
placenta is central to the pathophysiology of preeclampsia,
since the latter does not occur in its absence. Preeclampsia
is thought to occur in 2 stages [15]. In the ﬁrst stage,
abnormal placentation and maternal vascular remodeling
lead to placental underperfusion, hypoxia, and/or oxidative
stress, with placental release of factors which causes the
second stage of endothelial dysfunction and other man-
ifestations of preeclampsia. In the ﬁrst stage, defective
trophoblast diﬀerentiation and immune mechanisms related
to interactions between maternal T cells and placental
cytotrophoblast are hypothesized to be involved with the
inadequate placentation early in pregnancy. This leads to
inadequate remodeling of the spiral arteries during the ﬁrst
12 weeks of pregnancy. In the second stage, the onset of
systemic endothelial activation involving imbalance between
angiogenic and antiangiogenic cytokines occurs as a result
of insuﬃcient placental perfusion via the spiral arteries [35].
Another hypothesis involves abnormal syncytiotrophoblast
shedding into the maternal circulation, which incites an
inﬂammatory reaction [36].Stroke Research and Treatment 5
Consistent with the role of angiogenesis in the patho-
physiology of preeclampsia, several blood biomarkers of
angiogenesis have been studied to determine their predictive
valueforthedevelopmentofpreeclampsialaterinpregnancy.
Soluble ﬂt1, also known as soluble vascular endothelial
growth factor receptor 1 (sVEGFR1), is a protein produced
by the placenta which binds to placental growth factor
(PlGF) and VEGF, both of which are proangiogenic. Levels
ofsFlt1are low inearly pregnancy butrise steadily thereafter.
It is hypothesized that the balance between these factors
regulates placental angiogenesis, with increasing levels of
sFlt1 and decreasing levels of PlGF and VEGF exerting a
restraining eﬀect on placental vascular growth via a net
antiangiogenic eﬀect [37]. Endoglin is a coreceptor for
transforming growthfactor beta1 andbeta3,which ishighly
expressed on endothelial and syncytiotrophoblast surfaces.
Soluble endoglin is also antiangiogenic and increased in
preeclampsia [38].The combinationofthese biomarkerswas
studied using a nested case control cohort of the Calciumfor
Preeclampsia Prevention Trial [39]. When using a cutoﬀ for
high versus low levels of both markers, the combination of
high endoglin and high sﬂt1:PlGF ratios at 21 to 32 weeks
gestation was associated with 31.6-fold odds of preterm
preeclampsia and 30.8-fold odds of term preeclampsia [39].
Thesemarkersappeartobepromisingforidentifyingwomen
earlyenoughduringpregnancytoprovideearlyintervention.
7.Risksof StrokeLaterinLife
Although women with cerebrovascular manifestations of
preeclampsia are thought to be out of danger when the
baby is delivered, accumulated data show that women
with preeclampsia are at risk for stroke and cardiovascular
disease well after the postpartum period and child bearing
years [40–46]. A meta-analysis investigated the link between
preeclampsia and cardiovascular disease, stroke,and relevant
risk factors [4]. The cumulative odds ratios nicely illustrate
the association. For example, there is nearly a 4-fold odds of
developing hypertension (OR 3.7, 95% CI 2.70–5.05) and a
2-fold risk of ischemic heart disease (OR 2.16, 95% CI 1.86–
2.52) in women with preeclampsia. For fatal and nonfatal
stroke, the meta-analysis included 4 studies [43, 44, 47, 48]
with over 64,000 women with preeclampsia and about 900
ischemic strokes. The relative risks ranged from 1.39 to 5.08.
The cumulative relative risk was 2-fold with preeclampsia
(RR 2.16, 95% CI 1.86–2.52) [4].
In addition to maternal risk, children born to mothers
with preeclampsia pregnancies may also be at increased risk
for neurological problems and stroke. The Helsinki Birth
Cohort traced oﬀspring of the original cohort born between
1934and 1944in Helsinki, Finland [49].The hazard ratio for
all forms of stroke in oﬀspring of mothers with preeclampsia
was 1.9 (95% CI 1.2 to 3.0), and the hazard ratio was 1.4
for those born to women with pregnancies complicated by
gestational hypertension (95% CI 1.0–1.8). There was no
increased risk of coronary heart disease, however. Severe
preeclampsia was also associated with a reduced head
circumference at birth [49].
In addition to the risk of cardiovascular events, the
prevalence of cardiovascular risk factors and abnormal
vascular markers appears to be higher in women with a
history of preeclampsia. For example, women with a history
of preeclampsia about 20 years before being studied (mean
age at assessment 43 years) had higher diastolic blood
pressure and were more likelytobemenopausal than women
without preeclampsia [50]. Although there were no diﬀer-
ences in lipids, biomarkers of endothelial dysfunction such
as intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1) were elevated in the
preeclampsia group [50]. Other studies have shown that
women with a history ofpreeclampsia are morelikelytohave
higherinsulinlevelscomparedtocontrols[51].However,not
all studies have shown consistent diﬀerences in markers for
cardiovascular risk. Vickers et al. reported no diﬀerences in
levels of C reactive protein (CRP), von Willebrand factor,
or ﬁbrinogen in women with a history of preeclampsia
or gestational hypertension compared with controls [52].
As described in the meta-analysis and other longitudinal
studies, hypertension is the risk factor for cerebrovascular
disease that women with a history of preeclampsia and
gestational hypertension are most likely to develop [4, 43].
Women with a history of preeclampsia have also been
shown to have abnormal endothelial function well after
the puerperium. In a study of women in a minimum of
3 months following pregnancy, those with a prior history
of preeclampsia had lower brachial artery ﬂow mediated
dilation responses than women with normal pregnancies
(0.9% for those with multiple preeclamptic episodes, 2.7%
for single episode, and 4.7% for controls) [53]. Preeclampsia
was an independent predictor of ﬂow mediated dilation,
even after adjustment for family history, cardiovascular risk
factors such as cigarette smoking, lipids, glucose,and systolic
blood pressure [53]. Interestingly, when brachial artery
diameter in response to nitroglycerin, an endothelium-
independentresponse,wasmeasured,therewasnodiﬀerence
between groups [53]. Based on these results, preeclamp-
sia appears to have a chronic deleterious eﬀect on the
endothelium, regardless of other risk factors. Similarly, the
association between preeclampsia and impaired ﬂow medi-
ated dilation was also demonstrated in a separate, smaller
cohort measuring ﬂow mediated dilation 6 to 12 months
postpartum [54]. Another study of women with early
preeclampsia assessed 3 to 11 months postpartum reported
impaired microvascular skin reactivity, whereas endothelial-
independent activity was not signiﬁcantly diﬀerent from
controls [55]. More importantly for future risk of stroke,
in a study of visually evoked cerebral blood ﬂow responses
in the posterior cerebral artery measured with transcranial
Doppler ultrasound, women with a history of preeclampsia
have a dampened response to this stimulus [56]. Taking
into account the time from preeclampsia to the testing,
therealsoappearedtobediminishing cerebralhemodynamic
function over time associated with a history of preeclampsia.
Alternatively, this could represent worse function at baseline
[56]. In either case these ﬁndings provide another important
pathophysiologic basis for an increased risk for stroke in
women with a history of preeclampsia.6 Stroke Research and Treatment
8.Th eD uk eB i rthD atab as e
There are very few studies of women followed prospec-
tively after preeclampsia other than with administrative
databases, and many of the studies were limited to Caucasian
race/ethnicity. We performed an Institutional Review Board-
approved search of the Duke Perinatal Health Services
Outcomes Database, a medical record database of 42,263
women admitted to Duke University Medical Center from
1979 to 2005 by ICD-9 codes for preeclampsia (642.4–642.7)
andstroke(437.3–437.7)[42].Afterconﬁrmingwithmedical
record review that the timing of stroke was greater than 6
weeks postpartum at onset, 23 women met the inclusion
criteriaforhavinghadpreeclampsiaandalateradmission for
stroke. The median age at stroke onset was 38 (range 21–62),
18% or 78% were African American, and just over half had
ischemic stroke (13 ischemic strokes/TIAs, 8 hemorrhagic
strokes, and 2 subarachnoid hemorrhages). The majority
(70%) of women were between the ages of 18 and 34 at the
time of the last preeclamptic pregnancy (9% < age 17 and
22% over age 35). When preeclampsia was divided into mild
and severe, there was no association with stroke type, age
at stroke onset, or race/ethnicity. In terms of risk factors,
70% of these women had hypertension, 26% diabetes, 30%
hyperlipidemia, 59%smokedtobacco,13%used illicit drugs,
and 39% had had miscarriages [42]. In addition, 100%
of the women with hemorrhagic strokes had prepregnancy
hypertension, compared with 60% of the women with
ischemic stroke. We also found that the age of onset of
hypertension was not associated with the age at stroke [42].
This study was limited because of the small cohort size, the
lack of controls, and the inability to track hospitalizations
outside of the center where delivery occurred. However,
this was a novel longitudinal case series because these data
can provide guidance for how additional cohort studies
could be ideally designed to investigate the relationships
between stroke types and hypertension in women with a
history ofpreeclampsia. Forexample, based onthisdatabase,
future cohorts should enroll women who are no more than
5 years from delivery with preeclampsia at baseline. The
ongoing HyRAS study is designed to follow women in The
Netherlandswho are 2.5years post-preeclampsia for10years
to track the onset of cardiovascular disease [57]. Future
studies that include underrepresented minorities, such as
African American women, are needed to better understand
the risk of stroke after preeclampsia since these women are at
high risk for both preeclampsia and stroke.
9.PreventionofStrokeinWomen
Aspirin is an important prevention strategy for ischemic
stroke in women. Interestingly, it has also been used for pre-
vention for preeclampsia; therefore prevention with aspirin
represents another overlap between these two disorders. A
recent meta-analysis combined randomized clinical trials of
over 11,000 women randomized to low dose aspirin versus
placebo to prevent preeclampsia and intrauterine growth
restriction [58]. There was a signiﬁcant reduction in the rate
of preeclampsia with low dose aspirin started at 16 weeks
Hypertension, diabetes, prior preeclampsia, obesity,
family history, vitamin D deﬁciency
Ischemic or hemorrhagic
stroke, other
cardiovascular disease
Preeclampsia, mild or severe,
or gestational hypertension
Pregnancy
Persistent or new onset
hypertension, diabetes,
dyslipidemia, metabolic syndrome,
endothelial dysfunction, vitamin D
deﬁciency
Post-child bearing
Prepregnancy risk for preeclampsia
Figure 2
gestation or earlier (RR 0.47, 95% CI 0.34–0.65) in women
identiﬁed as moderate or high risk. The rate of intrauterine
growth restriction was reduced to a similar degree (RR 0.44,
95% CI 0.30–0.65). Since the rate of severe preeclampsia
was also reduced, cerebrovascular complications would also
theoretically be reduced as well. If aspirin was started after
16 weeks, the reduction in the rate of preeclampsia was no
longersigniﬁcant (RR0.81,95% CI 0.63–1.03)[58]. Caution
mustbeexercisedininterpretingthismeta-analysis, however,
since the inclusion criteria for individual trials of aspirin
therapy were heterogeneous. In all studies where aspirin had
beenstarted before 16 weeks, only womenidentiﬁed as being
at moderate to high risk for preeclampsia were included.
Although it appears that some cases of preeclampsia can
be prevented in women who are pregnant and at high risk
for preeclampsia, the best long-term prevention strategy for
these young and middle-aged women is currently unknown.
For prevention of stroke later in life, the emphasis should
be on recognizing and treating cardiovascular risk factors.
It is unlikely that treating all young women with aspirin
following the occurrence of preeclampsia without any other
risk factors would be dangerous because aspirin increases
the risk of hemorrhage. More studies are needed to identify
women at early risk of stroke, as well as heart disease, and
ultimately assess the risks and beneﬁts of various prevention
approaches.
Vitamin D deﬁciency has recently emerged as an impor-
tant potentially modiﬁable risk factor for both preeclampsia
and stroke. Women who are deﬁcient in vitamin D before
or during pregnancy are at increased risk for preeclampsia
[59]. Low serum levels of 25(OH)D are very common inStroke Research and Treatment 7
both developed and developing countries. In a population-
based study of vitamin D intake and risk of preeclampsia,
women with an estimated intake of 600–800IU of vitamin
D per day had reduced odds for preeclampsia compared
to women with an estimated intake of less than 200IU/day
(OR 0.76, 95% CI 0.6–0.95). Trials of supplementation with
calcium and vitamin D showed inconsistent eﬀects on the
risk of preeclampsia [60]. Large ongoing trials of vitamin
D supplementation in pregnancy as a strategy to prevent
preeclampsia and other adverse pregnancy outcomes are
ongoing. In a recent large electronic medical record database
analysis, a 51% relative increase in stroke prevalence was
noted in patients with very low versus normal vitamin D
levels (5.9% versus 3.9%; P<. 0001) [61]. The association
between vitamin D deﬁciency and increased risk for both
preeclampsia and stroke again suggests overlapping patho-
physiology for these disorders.
10.Summary
From a clinical perspective, preeclampsia should be regarded
as a risk factor for stroke in pregnancy as well as a harbinger
of future cerebrovascular disease, although there are many
gaps in our knowledge about who is at risk and when, as well
as how to best prevent preeclampsia and stroke in women
(Figure 2). There are many opportunities to intervene to
reduce morbidity and mortality, but the major obstacle cur-
rentlyisourabilitytoidentifywomenwhoareatriskforearly
cardiovascular disease. Given the overlap in risk factors, the
potential for early atherosclerosis, and the evidenceof lasting
endothelial dysfunction (i.e., subclinical vascular disease)
from the literature, several screening tests could be done to
risk-stratify women with preeclampsia. It is noteworthy that
thespectrumofhypertensivedisordersinpregnancyparallels
the risk for stroke and cardiovascular disease later in life.
Therefore,womenshouldbeactivelyscreenedforahistoryof
pregnancycomplicationsaspartofroutinepreventivecareor
during evaluation for stroke risk, even though they are well
past their child-bearing years. Using this simple historical
information is the ﬁrst step to risk stratiﬁcation. Further
research on the utility of subclinical vascular measurements,
such as cerebral or peripheral vasomotor reactivity, carotid
intimal medial thickness, coronary calciﬁcation, or clinical
and biochemical biomarkers, is needed to identify which
women with a history of preeclampsia are at increased risk
for future stroke.
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